Raúl Cabrera

Raúl Cabrera

Auto-generated profile, based on publicly available information

Raúl Cabrera

Department of Dermatology, Facultad de Medicina, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2018 in American Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
RCRaúl Cabrera
Raúl Cabrera
FRFrancisca Recule
Francisca Recule
This review presents the main challenges encountered when diagnosing unusual variants of malignant melanoma with the aim of raising awareness to allow application of the most appropriate treatment strategies. Although these melanomas are often rare, their misdiagnosis potentially jeopardizes patients’ health and survival, and has medicolegal implications. The clinical and histologic presentations of melanoma vary greatly, and assessment of uncommon melanomas can be difficult for practitioners because of their scarcity and resemblance to other dermatologic entities. The most problematic melanoma types are desmoplastic melanoma, polypoid melanoma, primary dermal melanoma, verrucous malignant melanoma, pigmented epithelioid melanocytoma, mucosal melanoma, follicular melanoma and melanoma with non-melanocytic differentiation. The two most difficult-to-diagnose subtypes of melanoma are the nevoid and the amelanotic melanomas. Some specific attributes of these variants can be more easily recognized with digital dermatoscopy, facilitating early detection and possibly avoiding invasive procedures. Key cases with the most notable clinical, dermatoscopic, and histopathologic features are presented, highlighting the practical issues of making an accurate diagnosis and choosing the best therapy.

1 April 2018 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
RCR Cabrera
R Cabrera
LHL Hojman
L Hojman
FRF Recule
F Recule
RSR Sepulveda
R Sepulveda
IDI Delgado
I Delgado
Vitiligo is an acquired depigmenting disorder. To date, there is no predictive model for its respons...

1 November 2015 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
RCR Cabrera
R Cabrera
JLJ Larrondo
J Larrondo
CWC Whittle
C Whittle
ACA Castro
A Castro
MGM Gosch
M Gosch
Is missing (Short communication)...

1 July 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
LHLia Paula Hojman
Lia Paula Hojman
RCRaúl Cabrera
Raúl Cabrera
CKClaudio Antonio Karsulovic
Claudio Antonio Karsulovic
FTFabian Tempio
Fabian Tempio
CPClaudio A Perez
Claudio A Perez
MLMercedes Natalia López
Mercedes Natalia López

1 May 2009 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
RCR. Cabrera
R. Cabrera
FDF. Daza
F. Daza

22 March 2024 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
ELEdinson López
Edinson López
RCRaúl Cabrera
Raúl Cabrera
CLCristóbal Lecaros
Cristóbal Lecaros
Background: Molecularly targeted therapies, such as monoclonal antibodies (mAbs) and Janus Kinase inhibitors (JAKis), have emerged as essential tools in the treatment of dermatological diseases. These therapies modulate the immune system through specific signaling pathways, providing effective alternatives to traditional systemic immunosuppressive agents. This review aims to provide an updated summary of targeted immune therapies for inflammatory skin diseases, considering their pathophysiology, efficacy, dosage, and safety profiles. Methods: The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A systematic search was conducted on PubMed over the past 10 years, focusing on randomized clinical trials, case reports, and case series related to targeted immune therapies in dermatology. Eligibility criteria were applied, and data were extracted from each study, including citation data, study design, and results. Results: We identified 1360 non-duplicate articles with the initial search strategy. Title and abstract review excluded 1150, while a full-text review excluded an additional 50 articles. The review included 143 studies published between 2012 and 2022, highlighting 39 drugs currently under investigation or in use for managing inflammatory skin diseases. Study limitations: The heterogeneity of summarized information limits this review. Some recommendations originated from data from clinical trials, while others relied on retrospective analyses and small case series. Recommendations will likely be updated as new results emerge. Conclusion: Targeted therapies have revolutionized the treatment of chronic skin diseases, offering new options for patients unresponsive to standard treatments. Paradoxical reactions are rarely observed. Further studies are needed to fully understand the mechanisms and nature of these therapies. Overall, targeted immune therapies in dermatology represent a promising development, significantly improving the quality of life for patients with chronic inflammatory skin diseases.